Member Info for bobfraeberks

Thanks jint. Looking forward to meeting up again.

Thanks Brand. We are used to medical science updates supporting the importance of INF 1 for fighting viral infections. This report you have found goes much further and directly justifies the current SNG strategy. We all "patiently" await un update on the execution of same strategy.

Having some difficulty posting my full message...

I left the meeting feeling quite positive and the risk reward ratio is now (again!) exceedingly favourable.

Many thanks to the fellow LTHs I met and a particular thanks for an excellent afternoon with jint, Doc83 and Wigster77. Already looking forward to the next AGM. Thanks guys.

Having some difficulty posting my full message...

• Very limited ability to combine results from our P2 and P3 trials with the upcoming trials. This is unfortunate as it diminishes our route to meaningful statistical data (p

• Very limited ability to combine results from our P2 and P3 trials with the upcoming trials. This is unfortunate as it diminishes our route to meaningful statistical data (p

• Trials will be US focused from John Ward (I heard 2in US and 1 in UK in the pub from a seemingly very knowledgeable investor)

• There may be no need for a placebo as we are targeting patients already gravely ill and will measure relative improvement

• Financing for P3 is not an issue. If we have the right data from P2 then BP will step in…one way or the other. Conversely…

• Of the type 1 interferons Beta is the most useful. Antibodies find it easier to bind to Alpha and Omega than to Beta…so we are on the right track

• Professor Holgate “excited” about the potential of SNG001 as a prophylactic depending on ability to assay for Interferon Beta deficiency and duration of benefit…e.g. If a dose provided significant benefit for say a month, then this could be a prescribed monthly medicine…I see huge commercial opportunity (especially in US) if both factors are positive

• Three million Americans hospitalised annually with viral infections. Not clear if this included historically high covid numbers but as this came from Richard in the context of future trials I would expect the it excluded this

• BP not interested in Covid only studies/data. Our trials will be on very highly targeted hospitalised from all viral infections

• Very limited ability to combine results from our P2 and P3 trials with the upcoming trials. This is unfortunate as it diminishes our route to meaningful statistical data (p

I'm coming to the AGM. Probably a waste of my travel cost but looking forward to a few beers with fellow LTH. I've lost BIG !

Thanks Titania. Much appreciated. Hope this information is incorporated into forthcoming H2 clinical trials.

Does anyone know if SNG have experienced job losses in recent times or do we have reason to believe that staff below BOD level have remained loyal. I ask this, as if the latter is true, it would be an additional strong signal that those in the know have reason to stay when hope seems in short supply.

Just read this in the Washington Post:

We ask that all start-up activities … be paused to allow Regeneron to evaluate the new variant and its potential impact to our planned clinical development trials,” a company memo sent to investigators running the trials said.
Scientists are worried that Evusheld could be useless by the end of the year, as new variants take over. The Food and Drug Administration warned this month that the drug is unlikely to protect against infection from BA.4.6, a strain that represents about 12 percent of the viruses circulating in the United States.
Bebtelovimab, the monoclonal made by Lilly, could also face a ticking clock as yet other mutations threaten to undermine its effectiveness.

Just to say I fully echo Manifesto’s comments. I was fully prepared to attend the AGM with my proxys but decided against it due to the high levels of Covid (I have a lung disease). SNG’s success means even more to me than recovering my rather large losses…and a Scotsman disnae like to lose money! ATB.

We need to ensure that the BOD open up and do not try to silence us(now poor) shareholders. This may require resolute and concerted action. There are a few on this board capable of organising and leading. I intend attending with my 350k votes. Over to you.

My guess is that they are protecting against being diluted below 25% due to issue of new shares. They will want to maintain the leverage that 25% provides.

To Maifesto: Just to say I echo every word from PJ as below, unfortunately including the magnitude of my losses. Lets hope you will have cause to be posting for some considerable time after the coming week . Thankyou. Bob

Well worth a second posting. Thanks Brighty1.

Sorry to see you leave Tony... a true class act. GL.

I was so excited that the RNS might be out this morning...that was my only question...never crossed my mind that we would fail primary and secondary points. Been invested since just before the £87m capital was raised and kept topping up on what I saw as a racing certainty! Like others, I question why there was zero positive spin in the RNS regarding deaths. In Phase 2, I recall three died and all were on the placebo. Adding that to P3 the death rate is more than halved when on SNG. If applicable that would be around 1000 lives pd saved in the USA...doesn't sound so bad when looking at it with those rose tinted glasses.

Overall testing in England showed BA.2 increased from 5.1% to 18% in just two weeks to the end of first week in February.
Hospitalisations were still falling…but of course there is the well known lag.

Quite concerning if BA.2 is more lethal (especially when you have a lung disease!).

K

Good for you Woody!